Joseph Rosenthal
YOU?
Author Swipe
View article: Phase 1 dose escalation study of the <scp>MDM2</scp> inhibitor milademetan as monotherapy and in combination with azacitidine in patients with myeloid malignancies
Phase 1 dose escalation study of the <span>MDM2</span> inhibitor milademetan as monotherapy and in combination with azacitidine in patients with myeloid malignancies Open
Background Mouse double minute‐2 homolog (MDM2) plays a key role in downregulating p53 activity in hematologic malignancies, and its overexpression is associated with poor outcomes. Methods This phase 1 study assessed the safety and effica…
View article: Data from ImmunoPET, [<sup>64</sup>Cu]Cu-DOTA-Anti-CD33 PET-CT, Imaging of an AML Xenograft Model
Data from ImmunoPET, [<sup>64</sup>Cu]Cu-DOTA-Anti-CD33 PET-CT, Imaging of an AML Xenograft Model Open
Purpose:Acute myeloid leukemia (AML) is a highly aggressive form of leukemia, which results in poor survival outcomes. Currently, diagnosis and prognosis are based on invasive single-point bone marrow biopsies (iliac crest). There is curre…
View article: Methods and figures from ImmunoPET, [<sup>64</sup>Cu]Cu-DOTA-Anti-CD33 PET-CT, Imaging of an AML Xenograft Model
Methods and figures from ImmunoPET, [<sup>64</sup>Cu]Cu-DOTA-Anti-CD33 PET-CT, Imaging of an AML Xenograft Model Open
Supplementary methods and figures
View article: Methods and figures from ImmunoPET, [<sup>64</sup>Cu]Cu-DOTA-Anti-CD33 PET-CT, Imaging of an AML Xenograft Model
Methods and figures from ImmunoPET, [<sup>64</sup>Cu]Cu-DOTA-Anti-CD33 PET-CT, Imaging of an AML Xenograft Model Open
Supplementary methods and figures
View article: Data from ImmunoPET, [<sup>64</sup>Cu]Cu-DOTA-Anti-CD33 PET-CT, Imaging of an AML Xenograft Model
Data from ImmunoPET, [<sup>64</sup>Cu]Cu-DOTA-Anti-CD33 PET-CT, Imaging of an AML Xenograft Model Open
Purpose:Acute myeloid leukemia (AML) is a highly aggressive form of leukemia, which results in poor survival outcomes. Currently, diagnosis and prognosis are based on invasive single-point bone marrow biopsies (iliac crest). There is curre…
View article: Severe, life‐threatening, and fatal chronic health conditions after allogeneic blood or marrow transplantation in childhood
Severe, life‐threatening, and fatal chronic health conditions after allogeneic blood or marrow transplantation in childhood Open
Background A comprehensive assessment of morbidity after allogeneic bone marrow transplantation (BMT) performed in childhood remains understudied. Methods Seven hundred eighty‐nine allogeneic BMT recipients who had survived ≥2 years after …
View article: Long-term follow up of patients with hematological malignancies treated with total body irradiation using intensity modulated radiation therapy
Long-term follow up of patients with hematological malignancies treated with total body irradiation using intensity modulated radiation therapy Open
Background With the advent of modern radiation treatment technologies such as intensity modulated radiation therapy (IMRT), there has been increasing interest in its use for total body irradiation (TBI) conditioning regimens for hematopoie…
View article: Role of radiotherapy in treatment of extramedullary relapse following total marrow and lymphoid irradiation in high-risk and/or relapsed/refractory acute leukemia
Role of radiotherapy in treatment of extramedullary relapse following total marrow and lymphoid irradiation in high-risk and/or relapsed/refractory acute leukemia Open
Background Total Marrow and Lymphoid Irradiation (TMLI) is a promising component of the preparative regimen for hematopoietic cell transplantation in patients with high-risk acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL). E…
View article: Total marrow irradiation (TMI): Addressing an unmet need in hematopoietic cell transplantation - a single institution experience review
Total marrow irradiation (TMI): Addressing an unmet need in hematopoietic cell transplantation - a single institution experience review Open
Purpose TMI utilizes IMRT to deliver organ sparing targeted radiotherapy in patients undergoing hematopoietic cell transplantation (HCT). TMI addresses an unmet need, specifically patients with refractory or relapsed (R/R) hematologic mali…
View article: Spoke‐Administered Thrombolysis Improves Large‐Vessel Occlusion Early Recanalization: The Real‐World Experience of a Large Academic Hub‐and‐Spoke Telestroke Network
Spoke‐Administered Thrombolysis Improves Large‐Vessel Occlusion Early Recanalization: The Real‐World Experience of a Large Academic Hub‐and‐Spoke Telestroke Network Open
Background Intravenous thrombolysis (IVT) before mechanical thrombectomy (MT) for large‐vessel occlusion (LVO) stroke is increasingly controversial. Recent trials suggest MT without IVT is reasonable for patients presenting directly to MT‐…
View article: Development and characterization of a preclinical total marrow irradiation conditioning-based bone marrow transplant model for sickle cell disease
Development and characterization of a preclinical total marrow irradiation conditioning-based bone marrow transplant model for sickle cell disease Open
Sickle cell disease (SCD) is a serious global health problem, and currently, the only curative option is hematopoietic stem cell transplant (HCT). However, myeloablative total body irradiation (TBI)-based HCT is associated with high mortal…
View article: Total marrow and lymphoid irradiation as conditioning in haploidentical transplant with posttransplant cyclophosphamide
Total marrow and lymphoid irradiation as conditioning in haploidentical transplant with posttransplant cyclophosphamide Open
Posttransplant cyclophosphamide (PTCy) platform has shown low rates of graft-versus-host disease (GVHD) and nonrelapse mortality (NRM) after haploidentical hematopoietic cell transplantation (HaploHCT). However, because of the limited dise…
View article: Direct to Angio‐Suite Large Vessel Occlusion Stroke Transfers Achieve Faster Arrival‐to‐Puncture Times and Improved Outcomes
Direct to Angio‐Suite Large Vessel Occlusion Stroke Transfers Achieve Faster Arrival‐to‐Puncture Times and Improved Outcomes Open
Background For patients with large vessel occlusion (LVO) stroke, time to treatment with endovascular thrombectomy is crucial to prevent infarction and improve outcomes. We sought to evaluate the hub arrival‐to‐puncture times and outcomes …
View article: Characterizing Reasons for Stroke Thrombectomy Ineligibility Among Potential Candidates Transferred in a Hub‐and‐Spoke Network
Characterizing Reasons for Stroke Thrombectomy Ineligibility Among Potential Candidates Transferred in a Hub‐and‐Spoke Network Open
Background Access to endovascular thrombectomy (EVT) is relatively limited. Hub‐and‐spoke networks seek to transfer appropriate large‐vessel occlusion stroke candidates to EVT‐capable hubs. However, some patients are ineligible upon hub ar…
View article: In a hub-and-spoke network, spoke-administered thrombolysis reduces mechanical thrombectomy procedure time and number of passes
In a hub-and-spoke network, spoke-administered thrombolysis reduces mechanical thrombectomy procedure time and number of passes Open
Background The utility of intravenous thrombolysis (IVT) prior to mechanical thrombectomy (MT) in large vessel occlusion stroke (LVO) is controversial. Some data suggest IVT increases MT technical difficulty. Within our hub-and-spoke teles…
View article: Abstract 1122‐000031: Reasons Thrombectomy Candidates Become Ineligible After Transfer for Treatment in a Hub‐And‐Spoke Telestroke Model
Abstract 1122‐000031: Reasons Thrombectomy Candidates Become Ineligible After Transfer for Treatment in a Hub‐And‐Spoke Telestroke Model Open
Introduction : The care of emergent large vessel occlusion (ELVO) stroke patients has been revolutionized by endovascular thrombectomy (EVT). Given its robust efficacy, it is crucial to optimize delivery to eligible patients. Within hub‐an…
View article: Abstract 1122‐000023: In a Hub‐and‐Spoke Network, Spoke‐Administered Thrombolysis Reduces Mechanical Thrombectomy Procedure Time and Number of Passes
Abstract 1122‐000023: In a Hub‐and‐Spoke Network, Spoke‐Administered Thrombolysis Reduces Mechanical Thrombectomy Procedure Time and Number of Passes Open
This meeting abstract was removed due to the OA licensing requirements of this journal. The full abstract is listed here : https://www.svin.org/files/SVIN_2021_Abstracts_for_Web.pdf
View article: 'Drip-and-ship' intravenous thrombolysis and outcomes for large vessel occlusion thrombectomy candidates in a hub-and-spoke telestroke model
'Drip-and-ship' intravenous thrombolysis and outcomes for large vessel occlusion thrombectomy candidates in a hub-and-spoke telestroke model Open
Background Randomized trials have not demonstrated benefit from intravenous thrombolysis among patients undergoing endovascular thrombectomy (EVT). However, these trials included primarily patients presenting directly to an EVT capable hub…
View article: P-023 Spoke-administered intravenous alteplase and outcomes for large vessel occlusion stroke patients in a hub-and-spoke telestroke model
P-023 Spoke-administered intravenous alteplase and outcomes for large vessel occlusion stroke patients in a hub-and-spoke telestroke model Open
Introduction The role of intravenous alteplase treatment for emergent large vessel occlusion (ELVO) stroke patients who ultimately undergo endovascular thrombectomy (EVT) has been questioned in recent randomized trials. However, most patie…
View article: Age and Acute Ischemic Stroke Outcome in North American Patients With COVID‐19
Age and Acute Ischemic Stroke Outcome in North American Patients With COVID‐19 Open
Background Acute ischemic stroke (AIS) in the context of COVID‐19 has received considerable attention for its propensity to affect patients of all ages. We aimed to evaluate the effect of age on functional outcome and mortality following a…
View article: Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma
Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma Open
Tisagenlecleucel is a CD19 chimeric antigen receptor (CAR) T-cell therapy approved for treatment of pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL) and adults with non-Hodgkin lymphoma (NHL). …
View article: Association between Very Low Dietary Protein Intake and Subsequent Falls in Community-Dwelling Older Adults in the United States
Association between Very Low Dietary Protein Intake and Subsequent Falls in Community-Dwelling Older Adults in the United States Open
Poor nutrition is linked to frailty and both poor nutrition and frailty are recognized risk factors for falls. This study examined the association between dietary protein intake and subsequent reported falls in community-dwelling older Ame…
View article: Developing and Monitoring a Standard-of-Care Chimeric Antigen Receptor (CAR) T Cell Clinical Quality and Regulatory Program
Developing and Monitoring a Standard-of-Care Chimeric Antigen Receptor (CAR) T Cell Clinical Quality and Regulatory Program Open
As the world of cellular therapy expands to include immune effector cell (IEC) products such as commercial chimeric antigen receptor (CAR) T cells, quality management (QM) professionals are faced with creating either new IEC stand-alone pr…
View article: Infection Rates among Acute Leukemia Patients Receiving Alternative Donor Hematopoietic Cell Transplantation
Infection Rates among Acute Leukemia Patients Receiving Alternative Donor Hematopoietic Cell Transplantation Open
Alternative graft sources, [umbilical cord blood (UCB), matched unrelated donors (MUD), or mismatched unrelated donors (MMUD)] enable patients without a matched sibling donor to receive potentially curative hematopoietic cell transplantati…